Who Paid My Doc
Richard Matern
Urology Salt Lake City, UT Medical Doctor
NPI 1851571590 CMS profile 1184694
324 10Th Ave, Ste 100, Salt Lake City, UT 84103
General payments
$57,685
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Richard Matern of Salt Lake City, UT is reported in the CMS Open Payments database as having received $57,685 across 209 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 95th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $9,591 | 29 | |
| 2024 | General | $3,543 | 24 | |
| 2023 | General | $2,037 | 22 | |
| 2022 | General | $7,290 | 20 | |
| 2021 | General | $665 | 25 | |
| 2020 | General | $1,000 | 21 | |
| 2019 | General | $33,557 | 68 |
Beside peers
- Richard Matern
- Urology median
- Middle half of Urology
- National median
In program year 2025, general payments to Richard Matern were reported at $9,591. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.
Show as a table
| Year | Richard Matern | Urology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $33,557 | $480 | $147–$1,201 | $163 |
| 2020 | $1,000 | $246 | $87–$645 | $114 |
| 2021 | $665 | $358 | $111–$1,000 | $132 |
| 2022 | $7,290 | $476 | $143–$1,263 | $149 |
| 2023 | $2,037 | $560 | $168–$1,461 | $160 |
| 2024 | $3,543 | $563 | $170–$1,464 | $164 |
| 2025 | $9,591 | $629 | $190–$1,620 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 15 drugsPart D claims
1,423
Drug cost
$102,405
Branded share of claims
24.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 83 | $69,311 | |
| Potassium Citrate Er Potassium Citrate | Brand | 51 | $8,215 | |
| Solifenacin Succinate | Generic | 184 | $6,878 | |
| Tamsulosin Hcl | Generic | 350 | $6,244 | |
| Finasteride | Generic | 341 | $5,318 | |
| Alfuzosin Hcl Er Alfuzosin Hcl | Brand | 93 | $2,334 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 83 | $2,123 | |
| Allopurinol | Generic | 37 | $545 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 45 | $522 | |
| Cephalexin | Generic | 26 | $345 |
The 10 drugs with the highest cost, of 15 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 45 billing codesPaid by Medicare
$84,356
Medicare patients
359
Services billed
1,573
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 65% | |
| Cancer | 52% | |
| Arthritis | 38% | |
| Diabetes | 31% | |
| Chronic kidney disease | 31% | |
| Ischemic heart disease | 27% | |
| Depression | 18% | |
| Atrial fibrillation | 17% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
209 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urology in Utah
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.